Flamel Technologies S.A. (ADR)  

(Public, NASDAQ:FLML)   Watch this stock  
Find more results for flml
+0.21 (1.48%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.21 - 14.59
52 week 9.30 - 26.09
Open 14.38
Vol / Avg. 81,380.00/289,236.00
Mkt cap 580.85M
P/E     -
Div/yield     -
EPS -1.70
Shares 40.25M
Beta 1.04
Inst. own 79%
Nov 18, 2015
Flamel Technologies SA at Jefferies Global Healthcare Conference
Nov 12, 2015
Q3 2015 Flamel Technologies SA Earnings Call
Nov 12, 2015
Q3 2015 Flamel Technologies SA Earnings Release
Sep 29, 2015
Flamel Technologies SA at Ladenburg Thalmann Life Sciences Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -62.73% -601.85%
Operating margin -30.60% -635.24%
EBITD margin - -141.48%
Return on average assets - -61.23%
Return on average equity - -1156.13%
Employees 109 -
CDP Score - -


33, avenue du Dr. Georges Levy, Venissieux Cedex, PARC CLUB DU MOULIN A VENT
+33-4-72783434 (Phone)
+33-4-72783435 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Flamel Technologies SA is a pharmaceutical company. The Company’s focus is on the development of safer and more efficacious formulations and other medical needs in the process. Micropump platform applied to sodium oxybate in a First-in-Man (FIM) clinical study in healthy volunteers. The Company’s products include Bloxiverz and Coreg CR. Bloxiverz (Neostigmine Methylsulfate Injection) is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Coreg CR, the lead product using the Company’s Micropump drug delivery platform. Coreg CR is an extended-release formulation of Coreg (carvedilol phosphate), a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors.

Officers and directors

Stephen H. Willard Non-Executive Chairman of the Board
Bio & Compensation  - Reuters
Michael S. Anderson Chief Executive Officer, Director
Bio & Compensation  - Reuters
Michael F. Kanan Chief Financial Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
Rafael Jorda Chief Operating Officer, Executive Vice President
Bio & Compensation  - Reuters
Sandra Hatten Senior Vice President - Quality and Regulatory Affairs
Bio & Compensation  - Reuters
Steven A. Lisi Senior Vice President - Business and Corporate Development
Bio & Compensation  - Reuters
Gregory J. Davis Vice President - Business and Corporate Development
Bio & Compensation  - Reuters
Gregg Stetsko Ph.D. Vice President - Research & Development
Age: 56
Bio & Compensation  - Reuters
Catherine Castan Director - Micropump Platform (Oral Drugs) and Intellectual Property
Bio & Compensation  - Reuters
Christian Kalita Pharmacist and Director - Quality Assurance and Regulatory Affairs
Bio & Compensation  - Reuters